Hemab Therapeutics Raises $135M in Series B Financing
Summary
Hemab Therapeutics, a Copenhagen, Denmark and Boston, MA-based clinical-stage biotechnology company developing prophylactic therapeutics for bleeding and thrombotic disorders, raised $135M in Series B funding. Christine Borowski, PhD, Vice President at Access, will join as a Board Observer. Led by Benny Sorensen, MD, PhD, CEO & President, Hemab Therapeutics is a clinical-stage biotech company. It is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. Its strategic guidance, Hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), and Congenital Antithrombin III Deficiency.